Shares of Ashland Inc. (NYSE:ASH – Get Free Report) reached a new 52-week low on Wednesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $68.01 and last traded at $68.43, with a volume of 312618 shares. The stock had previously closed at $71.16.
The basic materials company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.51). Ashland had a return on equity of 7.43% and a net margin of 7.95%. During the same quarter last year, the firm posted $0.45 EPS.
Ashland Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Saturday, March 15th. Stockholders of record on Saturday, March 1st will be paid a dividend of $0.405 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $1.62 dividend on an annualized basis and a dividend yield of 2.38%. Ashland’s dividend payout ratio (DPR) is currently 48.36%.
Wall Street Analysts Forecast Growth
View Our Latest Report on Ashland
Insider Buying and Selling
In other Ashland news, SVP Robin E. Lampkin sold 868 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $77.90, for a total value of $67,617.20. Following the sale, the senior vice president now owns 2,883 shares of the company’s stock, valued at approximately $224,585.70. This trade represents a 23.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Eric N. Boni sold 451 shares of the business’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $78.07, for a total value of $35,209.57. Following the transaction, the vice president now directly owns 14,182 shares of the company’s stock, valued at $1,107,188.74. This trade represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. 1.02% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Ashland
A number of hedge funds have recently made changes to their positions in the stock. Equitable Trust Co. lifted its stake in Ashland by 2.2% in the 3rd quarter. Equitable Trust Co. now owns 6,431 shares of the basic materials company’s stock valued at $559,000 after purchasing an additional 141 shares during the last quarter. Raymond James Trust N.A. increased its holdings in shares of Ashland by 5.5% during the third quarter. Raymond James Trust N.A. now owns 3,104 shares of the basic materials company’s stock worth $270,000 after buying an additional 163 shares in the last quarter. Creative Planning lifted its stake in shares of Ashland by 3.8% in the 2nd quarter. Creative Planning now owns 4,867 shares of the basic materials company’s stock valued at $460,000 after acquiring an additional 176 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Ashland by 5.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 3,532 shares of the basic materials company’s stock valued at $307,000 after acquiring an additional 182 shares in the last quarter. Finally, Central Pacific Bank Trust Division grew its position in Ashland by 16.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 1,677 shares of the basic materials company’s stock worth $146,000 after acquiring an additional 237 shares during the last quarter. 93.95% of the stock is currently owned by institutional investors and hedge funds.
Ashland Price Performance
The company has a current ratio of 2.44, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The firm has a market cap of $3.21 billion, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 1.14 and a beta of 0.87. The business has a 50-day moving average of $73.40 and a two-hundred day moving average of $82.21.
About Ashland
Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.
Further Reading
- Five stocks we like better than Ashland
- Investing In Automotive Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- Energy and Oil Stocks Explained
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Ashland Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ashland and related companies with MarketBeat.com's FREE daily email newsletter.